Tenjin Tomomi, Miyamoto Seiya, Miyake Nobumi, Ogino Shin, Kitajima Rei, Ojima Kazuaki, Arai Jun, Teramoto Haruki, Tsukahara Sachiko, Ito Yukie, Tadokoro Masanori, Anai Kiriko, Funamoto Yasuyuki, Kaneda Yasuhiro, Sumiyoshi Tomiki, Yamaguchi Noboru
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Hum Psychopharmacol. 2012 Jan;27(1):90-100. doi: 10.1002/hup.1276.
The purpose of this study was to evaluate the effects of blonanserin, a novel antipsychotic, on cognitive function in first-episode schizophrenia.
Twenty-four antipsychotic-naïve patients with first-episode schizophrenia participated in the study. Blonanserin was given in an open-label design for 8 weeks. The Brief Assessment of Cognition in Schizophrenia-Japanese language version (BACS-J) was administered as the primary outcome measure at baseline and 8 weeks. Clinical evaluation included the Positive and Negative Syndrome Scale (PANSS), the Schizophrenia Quality of Life Scale-Japanese language version (SQLS-J), and the Clinical Global Impression-Severity of Illness Scale (CGI-S). To exclude the possibility of retest effects on the BACS-J, 10 age-matched patients with chronic schizophrenia treated with blonanserin were tested at baseline and after an 8-week interval.
Twenty first-episode patients completed the study. Repeated measures analysis of covariance revealed a significant group-by-time interaction effect on the letter fluency task due to better performance in the first-episode group, but not in the control group. Main effect of time or group-by-time interaction effect on the Tower of London task was not significant; however, the first-episode group, but not the control group, showed substantial improvement with a moderate effect size. All items on the PANSS, SQLS-J, and CGI-S significantly improved after 8 weeks of treatment.
These results suggest that blonanserin improves some types of cognitive function associated with prefrontal cortical function.
本研究旨在评估新型抗精神病药物布南色林对首发精神分裂症患者认知功能的影响。
24例未使用过抗精神病药物的首发精神分裂症患者参与了本研究。布南色林采用开放标签设计给药8周。以精神分裂症认知功能简短评估-日语版（BACS-J）作为主要结局指标，在基线和8周时进行测量。临床评估包括阳性与阴性症状量表（PANSS）、精神分裂症生活质量量表-日语版（SQLS-J）以及临床总体印象-疾病严重程度量表（CGI-S）。为排除对BACS-J重测效应的可能性，对10例接受布南色林治疗的年龄匹配的慢性精神分裂症患者在基线和8周间隔后进行了测试。
20例首发患者完成了研究。重复测量协方差分析显示，由于首发组表现更好，在字母流畅性任务上存在显著的组×时间交互效应，而对照组未出现。时间的主效应或在伦敦塔任务上的组×时间交互效应不显著；然而，首发组而非对照组显示出有中等效应量的显著改善。治疗8周后，PANSS、SQLS-J和CGI-S的所有项目均显著改善。
这些结果表明，布南色林可改善与前额叶皮质功能相关的某些类型的认知功能。
